Quantification of apolipoprotein A‐I and B messenger RNA in heavy drinkers according to liver disease

P Mathurin, D Vidaud, M Vidaud, P Bedossa, V Paradis, V Ratziu, J Chaput, T Poynard – 1 January 1996 – It has previously been shown that, in heavy drinkers, serum apolipoprotein A‐I (ApoA‐I) levels are closely related to the degree of liver injury: they are at a maximum in patients with steatosis, begin to decrease in patients with fibrosis, and reach a minimum in patients with severe cirrhosis. In contrast with serum ApoA‐I variations, serum apolipoprotein B (ApoB) levels are stable.

The natural history of nonalcoholic fatty liver: A follow‐up study

Mohd R. Teli, Oliver F. W. James, Alastair D. Burt, Mark K. Bennett, Christopher P. Day – 1 December 1995 – Nonalcohol‐induced fatty liver is widely believed to be a benign condition with little or no risk of disease progression. There have been occasional reports of progression to cirrhosis but none in the absence of preexisting fibrosis on the index biopsy specimen even when co‐existing hepatitis was present (steatohepatitis). From our histological database (1978 to 1985), we identified 161 patients with fatty liver seen at our institution and traced the case notes of 156.

Hepatobiliary transport of hepatic 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase inhibitors conjugated with bile acids

Ernst Petzinger, Lutz Nickau, Jurgen A. Horz, Siegfried Schulz, Gunther Wess, Alfons Enhsen, Eugen Falk, Karl‐Heinz Baringhaus, Heiner Glombik, Axel Hoffmann, Stefan Müllner, Georg Neckermann, Werner Kramer – 1 December 1995 – To obtain prodrugs with affinity to liver parenchymal cells, the hepatic 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors HR 780 and lovastatin (syn. mevinolin) were conjugated with the bile acids cholic acid, taurocholic acid, and glycocholic acid.

Ciprofloxacin prevents the inhibitory effects of acute ethanol exposure on hepatic regeneration in the rat

Gerald Y. Minuk, Tony Gauthier, Xin K. Zhang, Gu Qi Wang, Norman M. Pettigrew, Frank J. Burczynski – 1 December 1995 – To determine whether the inhibitory effects of ethanol on hepatic regeneration could be prevented by ciprofloxacin, a fluroquinolone antibiotic with gammaaminobutyric acid (GABAA), receptor antagonist properties, adult, male Sprague‐Dawley rats (n = 6‐8/group) received intraperitoneal injections of saline, putrescine (a hepatic growth promotor, 50 mg/kg), or ciprofloxacin (100 mg/kg), followed 1 hour later by gastric gavage with saline or ethanol (5 g/kg).

Subscribe to